title: Detection of cell apoptosis in pelvic lymph nodes of patients with cervical cancer after neoadjuvant chemotherapy.
abstract: OBJECTIVE
  To investigate if the administration of neoadjuvant chemotherapy (NACT) reduces pelvic lymph node metastasis by inducing tumour cell apoptosis in patients with cervical cancer.
  
  
  METHODS
  This study enrolled patients with stage Ib2-IIb cervical cancer who underwent surgery with (NACT group) or without (control group) prior cisplatin-based chemotherapy. Immunohistochemical staining of caspase-3 and an in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling assay were used to measure the levels of apoptosis in primary tumours and pelvic lymph nodes.
  
  
  RESULTS
  A total of 185 patients participated in the study: 102 in the NACT group and 83 in the control group. Treatment was considered to be clinically effective in 69.6% (71/102) of the NACT group. The rate of metastasis in the NACT group (20.6%; 21/102) was significantly lower than the control group (42.2%; 35/83). The level of caspase-3 immunostaining and the rate of apoptosis in primary tumours and pelvic lymph nodes in the NACT group were significantly higher than in the control group.
  
  
  CONCLUSIONS
  NACT appeared to limit pelvic node metastasis by inducing tumour cell apoptosis in patients with cervical cancer.
authors.affiliation: National Hepatobiliary and Enteric Surgery Research Centre, Changsha, Hunan Province, China zhanghaiyan_nhec@163.com.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Zhang
authors.affiliation: National Hepatobiliary and Enteric Surgery Research Centre, Changsha, Hunan Province, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Peng
authors.affiliation: National Hepatobiliary and Enteric Surgery Research Centre, Changsha, Hunan Province, China.
authors.forename: Yangde
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery; D053148:Caspase 3 / Q000235:genetics* / Q000378:metabolism; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D015870:Gene Expression; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008198:Lymph Nodes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D010388:Pelvis; D012189:Retrospective Studies; D047368:Tumor Burden; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D053148:Caspase 3; D002945:Cisplatin
keywords: Cervical cancer; apoptosis; neoadjuvant chemotherapy; nodal metastasis